孔源性视网膜脱离修复手术后黄斑水肿的发生率、发病机制、危险因素和治疗。

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2025-02-21 eCollection Date: 2025-01-01 DOI:10.2147/OPTH.S489859
Enrico Bernardi, Neil Shah, Lorenzo Ferro Desideri, Jelena Potic, Janice Roth, Rodrigo Anguita
{"title":"孔源性视网膜脱离修复手术后黄斑水肿的发生率、发病机制、危险因素和治疗。","authors":"Enrico Bernardi, Neil Shah, Lorenzo Ferro Desideri, Jelena Potic, Janice Roth, Rodrigo Anguita","doi":"10.2147/OPTH.S489859","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To review the incidence, risk factors, and treatments for cystoid macular edema (CME) following rhegmatogenous retinal detachment (RRD) repair surgery.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across multiple databases. Relevant studies published within the last 20 years were selected and reviewed.</p><p><strong>Results: </strong>The incidence of CME following RRD repair ranges from 6% to 36%, with higher rates associated with silicone oil tamponade. Key risk factors include recurrent RRD, pre-existing proliferative vitreoretinopathy, older age, and post-RRD cataract surgery. Treatment options primarily focus on anti-inflammatory approaches, with topical NSAIDs and corticosteroids as first-line treatments. For persistent cases, intravitreal corticosteroid injections, particularly dexamethasone implants, have shown potential.</p><p><strong>Conclusion: </strong>CME remains a significant complication following RRD repair, impacting visual recovery. While various treatment options exist, management of persistent CME remains challenging. Better understanding of the underlying mechanisms of CME is required to develop more effective treatment strategies, particularly for cases resistant to current therapies.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"629-639"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853832/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cystoid Macular Edema Following Rhegmatogenous Retinal Detachment Repair Surgery: Incidence, Pathogenesis, Risk Factors and Treatment.\",\"authors\":\"Enrico Bernardi, Neil Shah, Lorenzo Ferro Desideri, Jelena Potic, Janice Roth, Rodrigo Anguita\",\"doi\":\"10.2147/OPTH.S489859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To review the incidence, risk factors, and treatments for cystoid macular edema (CME) following rhegmatogenous retinal detachment (RRD) repair surgery.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across multiple databases. Relevant studies published within the last 20 years were selected and reviewed.</p><p><strong>Results: </strong>The incidence of CME following RRD repair ranges from 6% to 36%, with higher rates associated with silicone oil tamponade. Key risk factors include recurrent RRD, pre-existing proliferative vitreoretinopathy, older age, and post-RRD cataract surgery. Treatment options primarily focus on anti-inflammatory approaches, with topical NSAIDs and corticosteroids as first-line treatments. For persistent cases, intravitreal corticosteroid injections, particularly dexamethasone implants, have shown potential.</p><p><strong>Conclusion: </strong>CME remains a significant complication following RRD repair, impacting visual recovery. While various treatment options exist, management of persistent CME remains challenging. Better understanding of the underlying mechanisms of CME is required to develop more effective treatment strategies, particularly for cases resistant to current therapies.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"19 \",\"pages\":\"629-639\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853832/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S489859\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S489859","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:回顾孔源性视网膜脱离(RRD)修复手术后膀胱样黄斑水肿(CME)的发生率、危险因素和治疗方法。方法:对多个数据库进行综合文献检索。选取并回顾了近20年来发表的相关研究。结果:RRD修复后CME的发生率从6%到36%不等,与硅油填塞相关的发生率更高。主要的危险因素包括复发性视网膜病变、已有的增殖性玻璃体视网膜病变、年龄增大和视网膜病变后的白内障手术。治疗选择主要集中在抗炎方法,局部非甾体抗炎药和皮质类固醇作为一线治疗。对于持续性病例,玻璃体内皮质类固醇注射,特别是地塞米松植入,已显示出潜力。结论:CME仍是RRD修复后的重要并发症,影响视力恢复。虽然存在各种治疗方案,但持续性CME的管理仍然具有挑战性。需要更好地了解CME的潜在机制,以制定更有效的治疗策略,特别是对当前治疗耐药的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cystoid Macular Edema Following Rhegmatogenous Retinal Detachment Repair Surgery: Incidence, Pathogenesis, Risk Factors and Treatment.

Purpose: To review the incidence, risk factors, and treatments for cystoid macular edema (CME) following rhegmatogenous retinal detachment (RRD) repair surgery.

Methods: A comprehensive literature search was conducted across multiple databases. Relevant studies published within the last 20 years were selected and reviewed.

Results: The incidence of CME following RRD repair ranges from 6% to 36%, with higher rates associated with silicone oil tamponade. Key risk factors include recurrent RRD, pre-existing proliferative vitreoretinopathy, older age, and post-RRD cataract surgery. Treatment options primarily focus on anti-inflammatory approaches, with topical NSAIDs and corticosteroids as first-line treatments. For persistent cases, intravitreal corticosteroid injections, particularly dexamethasone implants, have shown potential.

Conclusion: CME remains a significant complication following RRD repair, impacting visual recovery. While various treatment options exist, management of persistent CME remains challenging. Better understanding of the underlying mechanisms of CME is required to develop more effective treatment strategies, particularly for cases resistant to current therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信